The bile acid receptor farnesoid X receptor (FXR) regulates many aspects of lipid metabolism by various complex and incompletely understood molecular mechanisms. We set out to investigate the molecular mechanisms for FXR-dependent regulation of lipid and lipoprotein metabolism.
H igh plasma concentrations of low-density lipoprotein are a known risk factor for the development of cardiovascular disease. 1 Conversely, high plasma levels of high-density lipoprotein (HDL) are considered to be cardioprotective. 2 The putative protective mechanisms include the anti-inflammatory properties of HDL and its role in reverse cholesterol transport, a process involving transport of cholesterol from atherosclerotic lesions back to the liver for subsequent excretion in bile. 3 The importance of ATP binding cassette transporter A1 (ABCA1) in HDL synthesis was first realized when inactivating mutations in the ABCA1 gene were shown to be causative for Tangier disease. Patients with Tangier disease have very low HDL levels (<5% of normal levels). 4 Although ABCA1 is expressed in numerous cell types, tissue-specific deletion studies in mice demonstrated that hepatic, intestinal, and adipose tissue ABCA1 contribute 70% to 80%, 15% to 20%, and 15%, respectively, of the total plasma HDL. 5, 6 Although bone marrow transplantation studies in mice have identified a critical role for ABCA1 in mediating cholesterol efflux from macrophages to lipid-poor apoproteins, 7 there is no evidence that macrophage ABCA1 affects plasma HDL.
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Editorial, see p 1529 ABCA1 mRNA and protein levels are highly regulated by both transcriptional and posttranscriptional mechanisms. Activation of the liver X receptor (Nr1h3) results in increased transcription of the ABCA1 gene and increased levels of functional protein. 8, 9 More recent studies demonstrated that ABCA1 is also regulated posttranscriptionally by 2 microRNAs, miR-33a and miR-33b, derived from intronic regions of the sterol-response element-binding protein genes, SREBP-2 and SREBP-1, respectively. [10] [11] [12] [13] [14] Importantly, miR-33a is highly conserved across all species, whereas miR-33b is absent from rodents but present in primates. Studies with mice [10] [11] [12] [13] and nonhuman primates 15 demonstrated that modest changes in miR-33 levels (<2-fold) were sufficient to alter hepatic ABCA1 protein and plasma HDL levels (15%-20%). Low cellular sterol levels result in activation of SREBP-2 and subsequent induction of genes involved in cholesterol synthesis and uptake. 16 Simultaneous induction of miR-33 reduces ABCA1-dependent cholesterol efflux, thus providing a complementary mechanism to maintain cellular cholesterol levels. These studies show that SREBP-2 and miR-33 function together to maintain cellular cholesterol homeostasis.
High expression of the farnesoid X receptor (FXR; Nr1h4) is limited to liver, intestine, kidney, and the adrenal gland. 17 Activation of FXR regulates genes controlling synthesis, secretion, and resorption of bile acids; detoxification of hepatotoxins 18 ; maintenance of the intestinal barrier; and lipoprotein metabolism. 17, 19, 20 Although bile acids were originally identified as the endogenous ligands for FXR, 21, 22 subsequent studies demonstrated that specific bile acids also activate other nuclear receptors and the G-protein-coupled receptor, TGR5. 19, 20 Thus, a number of synthetic FXR-specific agonists, including GW4064 and WAY-362450, have been developed. 23, 24 In the present study, we used a recently described potent FXR agonist (GSK2324) 25 to identify hepatic microRNAs that are differentially regulated in vivo. Using a combination of gainand loss-of-function studies, we show that 1 of these microR-NAs, miR-144, is a direct FXR target that regulates hepatic ABCA1 protein levels and plasma HDL-cholesterol levels.
Methods

Mice, Diets, and Treatments
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Fxr −/− mice were backcrossed to C57BL/6J mice for 10 generations at the University of California, Los Angeles (UCLA). Floxed Fxr −/− mice were previously described 26, 27 and were backcrossed for 12 generations to a C57BL/6J background at UCLA before being crossed to Villin-Cre or Albumin-Cre mice (Jackson Laboratories). Mice were fed a standard chow diet (NIH31 modified mouse/rat diet, catalog No. 7013, Harlan Teklad) ad libitum. GSK2324 was a kind gift from Drs David Deaton and Tim Willson (GlaxoSmithKline). In the original publication by Bass et al, 25 the authors used the parent FXR agonist GW4064 to generate GSK8062. A quinolone derivative of the latter compound, GSK8062 1c, was also called GSK2324, 25 the term used in the present article. Importantly, the activation of FXR with GSK2324 is >100-fold greater than the effect on other nuclear receptors. 25 When indicated, 10-to 12-week-old mice were treated with either vehicle (water) or GSK2324 (30 mg/kg (mpk), once a day) for 3 days unless otherwise stated in the figure legends. Comparison between GSK2324 and GW4064 was performed after 3 doses of either vehicle (0.5% Tween 80) and either of the solubilized FXR agonists via intraperitoneal injections. For anti-miR treatments, mice were fed a Western diet (D12079B, Research Diets) for a total of 44 days. Anti-miRs were designed and synthesized by Regulus Therapeutics and delivered via intraperitoneal injections at 5 mpk. In all experiments unless otherwise stated, mice were fasted for 4 to 6 hours and euthanized in the early afternoon. All animal experiments were approved by the Office of Animal Research Oversight at UCLA.
MicroRNA Expression Profiling
Total RNA was extracted from mouse livers treated for 3 days with vehicle or GSK2324 using Qiagen miRNeasy Kit according to the manufacturer's instructions. Samples were prepared by pooling RNA from 2 to 3 livers, and triplicate samples per condition were analyzed. Microarray hybridization and scanning were performed at the UCLA Department of Pathology and Laboratory Medicine Clinical Microarray Core using Exiqon miRCURY LNA microRNA microarrays. Data analysis was performed using the limma and vsn packages in R (version 2.12.0). Calculated P values from the moderated t statistics were adjusted using the Benjamini-Hochberg method for multiple testing. MiRNAs with adjusted values of P<0.05 and fold change >25% were considered differentially expressed.
Plasma Lipid and Lipoprotein Analysis
All plasma lipid samples were analyzed by the Atherosclerosis Research Unit Lipid Core Facility, which is certified by the Centers for Disease Control lipid standardization program (Laboratory identification number, LSP-251). Plasma triacylglyceride and total and HDL-cholesterol were determined as previously described. 26 Plasma lipoprotein profiles were obtained by the modified Column Lipoprotein Profile method. 28 Briefly, 15 μL plasma was diluted with 60 μL saline, and 10 μL was injected into a Superose-6 column (GE Healthcare) using elution buffer (saline/2 mmol·L −1 EDTA per 0.01% sodium azide [pH 7.4]) at a flow rate of 0.6 mL/min at 40°C. The fast protein liquid chromatography eluate was immediately mixed with cholesterol reagent (Thermo Scientific) at a flow rate of 0.3 mL/min and incubated at 40°C in a 5-m KOT coiled reactor. The final mixture entered a spectrophotometric detector set at 500 nm, and the profiles were collected in real time using the LC solution software (Shimadzu).
Statistical Analysis
Statistical analysis was performed with Prism Graphpad software (version 5.0) or Microsoft Excel. Comparison between control and treatment group(s) was performed with either a Student t test or 1-way ANOVA, and statistical significance is shown as described in the figure legends.
Results
Activation of FXR In Vivo Induces Hepatic miR-144 and miR-451
To identify new pathways regulated by FXR, we used GSK2324, a novel, water-soluble FXR agonist. 25 As shown in Online Figure IA , treatment of wild-type, but not Fxr −⁄− , mice with GSK2324 increased the hepatic expression of the bile acid export pump (Bsep/Abcb11), a well-characterized FXR target gene. 20 Further more, induction of Bsep and other known FXR target genes was more pronounced in GSK2324treated compared with GW4064-treated mice, suggesting that GSK2324 is a more potent FXR agonist than GW4064 (Online Figure IB and data not shown).
Although activated FXR functions to directly induce target genes, FXR can also result in reduced expressions of many genes via indirect mechanisms. The latter is best exemplified by the FXR-dependent induction of small heterodimer partner (SHP) and FGF15/19 that together repress genes involved in bile acid synthesis. 19 We hypothesized that FXR may also induce miRNAs that in turn would act to negatively regulate specific genes. To test this hypothesis, we isolated total hepatic RNA from wild-type mice treated with vehicle or GSK2324 25 and performed miRNA expression profiling. Differential miRNA expression analysis was performed as described in the Methods section. This approach identified 5 miRNAs that were differentially expressed in the livers of GSK2324-treated C57BL/6 mice ( Figure 1A , Online Figure IC [Volcano plot], and Online Table I ). Of these 5 miRNAs, 3 were significantly induced (miR-144, -451, and -691; Online Table I ), but only miR-144 and -451 are highly conserved across many phyla. 29 In addition, miR-144 and miR-451 were previously reported to have high basal hepatic expression. 30 The finding that miR-144 and miR-451 are cotranscribed as a bicistronic cluster ( Figure 1B ) from an intergenic region on mouse chromosome 11 29, 31, 32 is also consistent with the coordinate induction of both miRNAs. Further, 2 mature miRNAs, miR-144 (also known as miR-144-3p) and miR-144* (also known as miR-144-5p) are generated from 1 of the stem loops ( Figure 1B ). TaqManbased real-time quantitative polymerase chain reaction confirmed the induction of miR-451, miR-144, and miR-144* in wild-type, but not Fxr −⁄− , mice treated with GSK2324 ( Figure  1C and Online Figure ID and IE). Importantly, all 3 miRNAs were also induced after treatment with the more commonly used FXR agonist, GW4064, when used at an equivalent dose ( Figure 1D and Online Figure IE ). The finding that miR-144, miR-144*, and miR-451 were induced to similar levels by GSK2324 ( Figure 1 and Online Figure I ) is in agreement with the bicistronic organization and common regulation of these microRNAs.
ABCA1 Is Regulated by miR-144
Using bioinformatic prediction tools, 33 we compiled a list of mRNAs targeted by either miR-144 (Online Table II ) or -451 using 4 different prediction softwares and focused on the 117 putative targets that were common to all 4 prediction programs for miR-144 (Online Table II) . Surprisingly, miR-451 had very few conserved target genes (not shown). Given the known role of FXR in the regulation of bile acid metabolism, we first searched for predicted miR-144 (or miR-451) target genes that would affect bile acid genes, but we failed to identify such targets (not shown). However, among the top predicted target genes for miR-144 was ABCA1. Analysis of the 3′-untranslated regions (UTRs) of ABCA1 mRNAs from numerous mammals identified 2 conserved putative miR-144 binding sites ( Figure 2A ). In addition, the mouse Abca1 3′ UTR contains 1 additional predicted miR-144 binding site not present in other species (data not shown).
To examine whether miR-144 directly targets ABCA1, we used a luciferase reporter plasmid containing the 3′ UTR from mouse Abca1 mRNA. Overexpression of miR-144, but not miR-451, reduced luciferase activity in a dose-dependent manner ( Figure 2B ). Deletion of the 2 predicted miR-144 binding sites rendered the ABCA1 reporter gene unresponsive to overexpression of miR-144 ( Figure 2C ). Individual mutations to the miR-144 binding site were not sufficient to abolish the response (data not shown). Consequently, we conclude that the 2 conserved miR-144 binding sites in the 3′ UTR of ABCA1 are sufficient and necessary for miR-144-dependent repression of ABCA1.
These overexpression studies used a pre-miR-144 expression plasmid that produces endogenously processed mature miR-144 and miR-144*. To investigate whether only 1 or both mature forms of miR-144 could regulate ABCA1, we transfected human embryonic kidney (HEK)293Ad cells with mimics of miR-144 or miR-144* or a control mimic, together with the luciferase ABCA1 3′ UTR reporter plasmid. As expected, only the miR-144 mimic, and not the miR-144* or control mimic, repressed the luciferase reporter plasmid ( Figure 2D ). The finding that the miR-144* mimic did not affect luciferase activity was expected because the ABCA1 3′ UTR does not contain predicted miR-144* binding sites. We conclude that mature miR-144 (miR-144-3p), but not miR-144* (miR-144-5p), is responsible for the regulation of ABCA1.
To investigate whether miR-144 overexpression would regulate endogenous ABCA1 mRNA or protein levels, we treated primary mouse hepatocytes with an adenovirus expressing pre-miR-144 or pre-miR-451, thus allowing endogenous processing and generation of mature miR-144 and miR-451, respectively. Overexpression of miR-144 in primary mouse hepatocytes led to decreased ABCA1 protein levels, although Abca1 mRNA levels were unexpectedly unchanged ( Figure 3A and 3B). Additionally, overexpression of miR-144 resulted in decreased efflux of cellular cholesterol to lipid-poor apoA-I ( Figure 3C ), consistent with the decrease in ABCA1 protein levels ( Figure 3B ). These effects were specific for miR-144 because overexpression of miR-451 had no effect on ABCA1 mRNA or protein levels or cholesterol efflux to apoA-I ( Figure 3A-3C ). Overexpression of miR-144 in a human hepatoma cell line (Hep3B) also resulted in a decrease in both ABCA1 protein and efflux of cholesterol to apoA-I in the absence of a change in ABCA1 mRNA ( Figure 3D-3F) . These results demonstrate that overexpression of miR-144 results in decreased ABCA1 protein levels in both mouse and human hepatocytes, suggesting that the mechanism may be conserved across these species.
Overexpression of miR-144 in Mice Decreases Hepatic ABCA1 Protein and Plasma HDL-Cholesterol
To evaluate the in vivo consequences of hepatic overexpression of miR-144, we injected wild-type mice on a chow diet with either a control adenovirus or an adenovirus expressing pre-miR-144 driven by a U6 promoter. This pre-miR-144 requires endogenous processing to produce mature, active miR-144. After 5 days, hepatic mature miR-144 levels increased 60% ( Figure 4A) , an increase similar to that observed after treatment of mice with the FXR agonist GSK2324 (compare Figure 4A and Figure 1C) . Importantly, the increase in miR-144 was associated with a significant decrease in hepatic ABCA1 protein without a change in Abca1 mRNA ( Figure  4B ). The expression of other genes involved in lipoprotein and HDL biogenesis and metabolism (SR-BI, ApoAI, ApoAII, ApoE) was unchanged (Online Figure IIA) . This result was expected because none of these genes were present in the list of predicted miR-144 target genes generated by 4 independent algorithms (Online Table II ). In contrast, the expressions of a known miR-144 target, nuclear factor-erythroid 2-related factor 2 (Nfe2l2, also known as NRF2), 34 and a novel target predicted from our in silico analysis (Rarβ; Online Table II) were modestly decreased (Online Figure IIA) . Importantly, total plasma and HDL-cholesterol ( Figure 4C and 4D) levels decreased in response to hepatic miR-144 overexpression in the absence of changes in plasma triacylglycerides (Online Figure  IIB) , consistent with a specific effect of miR-144 overexpression on plasma HDL-cholesterol. Taken together, these data demonstrate that a modest increase in hepatic miR-144 levels in vivo is sufficient to reduce both hepatic ABCA1 protein and plasma HDL-cholesterol.
In Vivo Silencing of miR-144 Increases Hepatic ABCA1 Protein and Plasma HDL
Having used gain-of-function approaches to show the effect of overexpression of hepatic miR-144, we next investigated whether loss of function would raise hepatic ABCA1 and plasma HDL-cholesterol. Prior studies in mice and monkeys have successfully used chimeric 2′-fluoro/2′-methoxyethyl, phosphorothioate backbone-modified anti-miRs to reduce the expression of many miRNAs, including miR-122 and miR-33. 15, 35 Consequently, we generated antisense oligonucleotides that specifically target miR-144 (also known as miR-144-3p) and administered them to C57BL/6 mice fed a Western diet for 6 weeks. Biweekly anti-miR treatments were initiated after 2 weeks on the Western diet and continued for an additional 4 weeks before termination of the experiment. Anti-miR-144 or control anti-miR treatments did not affect body weight (Online Figure IIIA) or increase plasma alanine aminotransferase and aspartate aminotransferase levels compared with vehicle-treated mice (Online Figure IIIB) . Plasma lipids were quantified after 2 weeks (Online Figure IIIC) and after 4 weeks ( Figure 5 ) of anti-miR treatments at the termination of the experiment.
Anti-miR-144 treatment significantly reduced hepatic miR-144 levels ( Figure 5A ). However, analysis of absolute changes in the levels of silenced microRNAs may be confounded by the formation of stable intracellular miRNA:anti-miR complexes. 35 Nonetheless, the fact that reduced miR-144 levels were detected suggests that, at the very least, the anti-miR-144 accumulated in the livers of treated mice and likely reduced miR-144 availability. Importantly, anti-miR-144 treatment for 4 weeks resulted in increased levels of hepatic ABCA1 protein, total plasma, and HDL-cholesterol without significantly affecting Abca1 mRNA ( Figure 5B -5D) or plasma triacylglyceride levels (data not shown). The increase in plasma HDL-cholesterol was also observed after 2 weeks of anti-miR-144 treatment (Online Figure IIIC) . Silencing of miR-144 for 4 weeks had no effect on hepatic scavenger receptor B1 (Scarb1, also known as SR-B1) and ApoAI mRNA and, as expected, induced the expression of both Nfe2l2 and Rarβ (Online Figure IIID) . Surprisingly, anti-miR-144 treatment also increased the expression of hepatic ApoAII and ApoE mRNAs (Online Figure IIID) . This result may be attributable to indirect regulation because the 3′ UTRs of ApoAII and ApoE do not contain putative miR-144 binding sites, and neither ApoAII or ApoE mRNAs were altered by miR-144 overexpression (Online Figure IIA) . Taken together, these results demonstrate that silencing of miR-144 results in increased hepatic ABCA1 protein levels and plasma HDL-cholesterol.
Next, we determined whether acute silencing of miR-144 in mice fed a chow diet also affected plasma lipid levels. We treated male, chow-fed C57BL/6 mice with 2 treatments of anti-miR-144 (5 mpk) on days 1 and 4 and euthanized the mice on day 7. Analysis of hepatic miR-144 levels indicated a significant reduction in miR-144 levels (Online Figure IVA) , suggesting that the anti-miR-144 was likely present in the liver. Moreover, miR-144 silencing caused a modest increase in ABCA1 protein without affecting mRNA (Online Figure  IVB) , consistent with previous experiments. Importantly, silencing miR-144 for 7 days was sufficient to elevate plasma total and HDL-cholesterol levels (Online Figure IVC and IVD), although these changes were more modest than silencing miR-144 for 28 days in the presence of a Western diet. Nonetheless, these results demonstrate that silencing miR-144 both acutely and chronically in chow-fed or Western diet-fed mice results in increased plasma HDL levels.
MiR-144 Is a Direct FXR Target
FXR activation in the liver directly induces FXR target genes, which, in turn, act as effectors for the FXR-dependent changes in bile acid and lipid metabolism. In addition, activation of intestinal FXR induces FGF15/19, and this secreted protein then modulates hepatic gene expression. 19, 20 To identify whether hepatic or intestinal FXR is required for the induction of miR-144 and -451 in the liver, we generated tissue-specific FXR knockout mice by crossing mice containing floxed FXR alleles to mice that express either villin-or albumin-driven Cre recombinase. This approach generated mice that do not express FXR in the intestine (I-Fxr −⁄− ) or liver (L-Fxr −⁄− ), respectively. Treatment of the wild-type (floxed) Fxr mice or I-Fxr −⁄− mice with GSK2324 resulted in normal induction of both miR-144 and -451 ( Figure 6A) . In contrast, miR-144, miR-451 ( Figure  6A) , and miR-144* (Online Figure IF) were not induced in the livers of L-Fxr −⁄− mice, demonstrating the requirement for hepatic FXR for the induction of miR-144/-451. Consistent with this result, we show that GSK2324 treatment of wild-type or I-Fxr −⁄− mice for 3 days resulted in decreased total plasma and HDL-cholesterol levels, whereas plasma lipid levels were not decreased after treatment of L-Fxr −⁄− mice with GSK2324 ( Figure 6B ). Moreover, the hyperlipidemic effect previously described in whole-body Fxr −⁄− mice 36 was also observed in untreated L-Fxr −⁄− , but not I-Fxr −⁄− , mice ( Figure 6B) . Together, these studies identify hepatic FXR as being critical for the induction of miR-144 and for the GSK2324-dependent decrease in plasma cholesterol levels. The change in plasma cholesterol levels is likely a result of multiple mechanisms because FXR also induces the expression of hepatic Scarb1, the HDL receptor (Online Figure VA) . 26 To determine whether miR-144/-451 is a direct target of FXR, we analyzed data from a genome-wide hepatic FXR response element (FXRE) chromatin immunoprecipitation study. 37 This analysis identified an FXRE located ≈12 kb upstream of the mouse miR-144/-451 locus (Online Figure  VB) , whereas no FXRE was identified in the proximal promoter. Importantly, this FXRE was both conserved in rats and flanked by an additional nuclear receptor half-site (TGGCACT; Online Figure VB) , consistent with previous findings for many but not all FXREs. 37, 38 To investigate whether the distal putative FXRE functions as a bona fide FXRE, we generated a reporter plasmid containing 3 copies of the FXRE upstream of a minimal thymidine kinase promoter driving a luciferase reporter gene. FXR overexpression and activation with GSK2324 caused a dose-dependent induction in the miR-144 FXRE reporter plasmid (Online Figure VC) . In contrast, luciferase activity was not induced when the 3 copies of the FXRE were mutated (Online Figure VC) .
In contrast to mice and rats, analysis of the human genomic region corresponding to the 3-kb region upstream of the human miR-144/-451 locus identified a putative FXRE. This response element is also conserved in nonhuman primates Figure 6 . Hepatic farnesoid X receptor (FXR) is required for the induction of miR-144 and the hypocholesterolemic effects of GSK2324. The miR-144/-451 cluster is a direct FXR target. Liver-specific (L-KO) and intestine-specific knockout (I-KO) Fxr −⁄− mice and Fxr +⁄+ (floxed) littermate (WT) mice were treated with vehicle or GSK2324 for 3 days at 30 mpk/d. A, Hepatic miR-144 and miR-451 levels were determined by TaqMan real-time quantitative polymerase chain reaction (RT-qPCR), and (B) plasma total and high-density lipoprotein (HDL)-cholesterol levels were determined as described in the Methods section. C, The human miR-144/451 promoter cloned into a luciferase reporter plasmid was transfected together with a β-galactosidase expression plasmid and increasing amounts of pcDNA human FXRα2 expression plasmid into Hep3B cells in the presence or absence of GSK2324 (1 μmol/L). Promoter activity was normalized to β-galactosidase activity shown as fold changes. D, Hepatic Abca1 mRNA and (E) ABCA1 protein levels were determined by RT-qPCR or Western blotting, respectively, in Fxr +⁄+ (WT) and Fxr −⁄− (KO) mice treated with vehicle or GSK2324 (30 mpk/d, 3 days; n=5-9 each group). Data are shown as mean±SEM. Significance was measured with 1-way ANOVA or the Chromatin Immunoprecipitation-SeqS student t test. *P<0.05, ***P<0.001. Figure VB) . A luciferase reporter gene under the control of the human miR-144/-451 promoter was induced after coexpression of FXR and treatment with GSK2324 ( Figure  6C ). The FXR-dependent activation of the human promoter was abolished when the predicted single FXRE was mutated ( Figure 6C ). Thus, we conclude that both primates and rodents contain distinct functional FXREs in the miR-144/-451 loci that are important for the FXR-mediated induction of both miR-144 and -451. The data we have described thus far suggest that treatment of mice with GSK2324 will result in a decrease in hepatic ABCA1 protein. To test this hypothesis, we treated wild-type and Fxr −⁄− mice with GSK2324 for 3 days. FXR activation resulted in a modest decrease in Abca1 mRNA but a more pronounced decrease in ABCA1 protein ( Figure 6D and 6E ). This effect was specific because treatment of Fxr −⁄− mice did not change either ABCA1 mRNA or protein levels ( Figure 6D and 6E). These results are consistent with an FXR-dependent, posttranscriptional regulation of ABCA1.
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Discussion
Previous studies have demonstrated that treatment of mice and rats with FXR agonists such as GW4064 or WAY-362450 results in decreased plasma triacylglyceride and cholesterol levels. 24, 26, 39 FXR agonists were also shown to induce the hepatic expression of Scarb1 mRNA and protein that could explain, at least in part, the FXR-dependent reduction in plasma HDL. 26 The results presented here identify a complementary, previously unrecognized pathway that links hepatic FXR activation to induction of miR-144 and subsequent reduction in hepatic ABCA1 protein. We used both gain-of-function and loss-offunction studies to show that changes in the levels of hepatic miR-144 are sufficient to regulate hepatic ABCA1 protein and plasma HDL-cholesterol. This effect was specific because plasma triacylglyceride levels were unaffected by changes in miR-144 levels. The physiological importance of this FXRdependent dual regulation of plasma HDL levels through Scarb1 and miR-144 remains to be clearly elucidated but may be related to efficient channeling/partitioning of intrahepatic cholesterol into bile.
A very recent report showed that enhanced HDL uptake via overexpression of Scarb1 increased hepatic cellular cholesterol, which was then preferentially transported into bile, but the effect required blunted ABCA1 activity, which was achieved with probucol. 40 These results suggest that induction of Scarb1 alone is not sufficient to prevent the recirculation of cholesterol, which may then be resecreted into nascent HDL via ABCA1. Thus, the present data suggest that FXR not only promotes the clearance of circulating HDL (via Scarb1) but also minimizes the resecretion of intracellular sterols into new HDL (as illustrated in Figure 7 ). Together, these data suggest that FXR activation induces uptake of plasma HDLcholesterol into the liver and subsequently facilitates the excretion of cholesterol and cholesterol-derived bile acids into the bile. Indeed, we have previously demonstrated that FXR activation with GW4064 increases reverse cholesterol transport, 26 consistent with the altered sterol flux. The findings reported in the present study showing that FXR reduces hepatic ABCA1 protein via a posttranscriptional mechanism provides important evidence supporting this complex directional movement of cholesterol (Figure 7 ). FXR activation in vivo with GSK2324 or GW4064 (solubilized in 0.5% Tween 80) did not induce the expression of the transporters ABCG5/G8 (not shown), which are involved in the transport of cholesterol into the bile. 41 Importantly, in the sterol flux model proposed by Annema et al, 40 an increase in Abcg5/Abcg8 expression was not required, suggesting that endogenous levels of ABCG5/ G8 protein are sufficient to mediate cholesterol movement into the bile.
Hepatic miR-144 levels were induced to a similar extent in GSK2324-treated wild-type and I-Fxr −⁄− mice ( Figure 6A) , demonstrating that intestinal FXR has no role in regulating hepatic miR-144 levels or the hypolipidemic effects of FXR activation. These data, together with the observation that intestinal miR-144 levels were low/undetectable, 30 suggest that the effects noted in the present report are dependent on hepatic miR-144 but independent of intestinal miR-144.
Recent studies demonstrated that miR-33 represses the expression of ABCA1 mRNA and protein. [10] [11] [12] Importantly, the complementary sequences in the mouse or human ABCA1 3′ UTR that bind miR-33 are quite distinct from the sites that bind miR-144. Thus, miR-33 and miR-144 presumably regulate ABCA1 mRNA independently and in response to different signals that result from either changes in cellular sterol levels and subsequent SREBP-2 transcription or changes in hepatic FXR activation, respectively. It is also interesting to note that miR-144 regulates ABCA1 largely at the protein level. The precise mechanism by which miRNAs regulate the levels of their targets is currently not well understood, and it will be important to determine precisely how miR-144 regulates its various targets, including ABCA1. Some studies have suggested that the region outside the seed sequence may play a role in determining whether an miRNA modulates translational arrest (reduced complementarity) or mRNA destabilization (with more complementary base pairing). 42 Interestingly, the very first miRNA that was discovered (lin-4) was indeed shown to largely affect translation of its target, lin-14. 43, 44 Further studies are required to determine the precise mechanism for how miR-144 regulates ABCA1.
The observation that hepatic miR-144 regulates plasma lipid levels was unexpected. Indeed, miR-144 and miR-451 were initially discovered as microRNAs processed independently of Dicer. 29, 31, 32 Mice lacking both miR-144 and miR-451 45, 46 or lacking miR-451 alone 45 exhibited impaired late erythroblast maturation, a phenotype attributed solely to miR-451. Thus, the function of miR-144 remained an enigma. However, because the liver is not involved in erythroblast maturation in adulthood, it suggested that miR-144 or miR-451 had additional functions in adult mammals. The present report provides insight into 1 function of hepatic miR-144 in adult mammals.
The present study demonstrates that the mouse and human miR-144/-451 loci are direct targets for FXR. Chromatin immunoprecipitation sequence data had previously identified a putative FXRE 12 kb upstream of the transcriptional start site of the mouse miR-144/-451 locus. 37 In the present study, we demonstrated that this FXRE functions to drive transcription of a luciferase reporter gene in an FXR-and GSK2324-dependent manner (Online Figure VC) . In addition, we identified a functional FXRE in the proximal promoter of human miR-144/-451 ( Figure 6C ). These data demonstrate that the human and mouse miR-144/-451 cluster is a direct target of FXR, although the relative position of the functional FXREs upstream of the miR-144/-451 cluster is not strictly conserved. This is not without precedent because the precise location of binding sites for many transcription factors, including other nuclear receptors in the liver, was previously shown not to be strictly conserved, although regulation of the target genes themselves was maintained. 47 Curiously, the mouse FXRE is also conserved in rats and the human FXRE is conserved in the macaque (Online Figure  VB) , suggesting an evolutionary divergence in higher mammals but, nonetheless, a conserved response.
In summary, the current studies identify a new pathway that links FXR activation to induction of hepatic miR-144 and subsequent repression of ABCA1 and plasma HDL-cholesterol. In mice, FXR activation has been shown to increase miR-144 (in the present study), to lower plasma HDL, to increase reverse cholesterol transport, 20 and to lower atherosclerosis. 39 Interestingly, FXR agonists are currently in phase III clinical trials. 20 However, it is not known whether treatment of humans with FXR agonists will produce similar effects on HDL levels or properties, reverse cholesterol transport, and atherosclerosis.
Recent studies in which miR-33, which also targets ABCA1, was silenced with antisense oligonucleotides were reported to promote regression of preexisting atherosclerotic lesions in Ldlr − ⁄ − mice 48 but to have no effect on lesion development. 49 Genetic loss of miR-33 in a different atherosclerosis mouse model (Apoe − ⁄ − mice) showed increased HDL and reduced lesions. 50 In contrast, bone marrow transplantation from miR-33 − ⁄ − Apoe − ⁄ − double-knockout mice into Apoe − ⁄ − mice showed a decrease in the lipid content of lesions, although lesion size and plasma HDL levels were not significantly different from control Apoe − ⁄ − mice transplanted with miR-33 +/+ Apoe − ⁄ − bone marrow. 50 Thus, although macrophage miR-33 seems to control the lipid content of lesions, the relative importance of hepatic or macrophage-derived miR-33 in controlling lesion size in different animal models remains unclear. In contrast to miR-33, the expression and regulation of miR-144 in macrophages, a cell type that does not express FXR, have not yet been reported. Moreover, the long-term effect of altering miR-144 levels in the liver or other tissues on the development or regression of atherosclerosis remains to be determined.
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